Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Editas Medicine ( (EDIT) ) has provided an update.
On October 9, 2025, Editas Medicine presented in vivo preclinical proof-of-concept data for their experimental therapy, EDIT-401, at the European Society of Gene and Cell Therapy Congress. The therapy aims to significantly reduce LDL-cholesterol by upregulating the LDL receptor, showing promising results in non-human primates and mice with reductions exceeding 90% within 48 hours of a single dose, potentially impacting the company’s position in the gene therapy market.
The most recent analyst rating on (EDIT) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Editas Medicine stock, see the EDIT Stock Forecast page.
Spark’s Take on EDIT Stock
According to Spark, TipRanks’ AI Analyst, EDIT is a Neutral.
Editas Medicine’s overall stock score is primarily influenced by its financial challenges, including negative cash flow and lack of revenue growth. However, recent corporate events showcasing promising advancements in gene editing provide a positive outlook, partially offsetting financial concerns. Technical indicators suggest a neutral to slightly bearish short-term trend, while valuation metrics reflect the typical high-risk, high-reward nature of biotech investments.
To see Spark’s full report on EDIT stock, click here.
More about Editas Medicine
Editas Medicine, Inc. operates in the biotechnology industry, focusing on developing gene editing therapies using CRISPR technology to address a range of genetic diseases.
Average Trading Volume: 2,308,404
Technical Sentiment Signal: Hold
Current Market Cap: $353.4M
For an in-depth examination of EDIT stock, go to TipRanks’ Overview page.